Literature DB >> 330081

Renal clearance and tissue accumulation of gentamicin.

J J Schentag, W J Jusko.   

Abstract

Multiple-dose studies of gentamicin pharmacokinetics were performed in 2 treated patients. After the final dose, serum and urine concentration declined in biphasic fashion with beta half-lives of 87 and 173 hr. Recovery of the total dose administered required urine collection for at least 10 to 20 days after the last dose. A two-compartment model was used to describe the biphasic decline in serum concentrations, to simulate all measured concentrations during treatment, and to predict the amount of gentamicin in the tissue compartment. Analysis of autopsy tissues yielded the predicted amount of drug. A linear two-compartment model adequately quantitates gentamicin disposition until about 4 days after cessation of therapy when gentamicin renal clearance begins to decline because of tubular reabsorption.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330081     DOI: 10.1002/cpt1977223364

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose.

Authors:  N Isoherranen; E Lavy; S Soback
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.

Authors:  Liviawati Wu; Murad Melhem; Raju Subramanian; Benjamin Wu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-06       Impact factor: 2.745

3.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 4.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

5.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

6.  Aminoglycoside dosages and nephrotoxicity: quantitative relationships.

Authors:  Florent Rougier; Michel Ducher; Michel Maurin; Stéphane Corvaisier; Daniel Claude; Roger Jelliffe; Pascal Maire
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nephrotoxicities.

Authors:  M E Brier; P R Mayer; R A Brier; D Visscher; F C Luft; G R Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

9.  Altered tobramycin pharmacokinetics during chemoprophylaxis in bladder surgery.

Authors:  F Bressolle; P Joubert; A Gouby; P Costa; M Laracine; T Rebière
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Authors:  Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.